DOCSLIB.ORG

Metabolske Sykdommer V02

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabolske Sykdommer V02 2/1/2021 Metabolske sykdommer v02 Avdeling for medisinsk genetikk Metabolske sykdommer Genpanel, versjon v02 * Enkelte genomiske regioner har lav eller ingen sekvensdekning ved eksomsekvensering. Dette skyldes at de har stor likhet med andre områder i genomet, slik at spesifikk gjenkjennelse av disse områdene og påvisning av varianter i disse områdene, blir vanskelig og upålitelig. Disse genetiske regionene har vi identifisert ved å benytte USCS segmental duplication hvor områder større enn 1 kb og ≥90% likhet med andre regioner i genomet, gjenkjennes (https://genome.ucsc.edu). For noen gener ligger alle ekson i områder med segmentale duplikasjoner: AQP7, ASNS, ATAD3A, CA5A, CYCS, CYP11B1, CYP11B2, CYP21A2, GBA, GGT1, MSTO1, PIGC, SDHA, SLC6A8, SORD Vi gjør oppmerksom på at ved identifiseringav ekson oppstrøms for startkodon kan eksonnummereringen endres uten at transkript ID endres. Avdelingens websider har en full oversikt over områder som er affisert av segmentale duplikasjoner. ** Transkriptets kodende ekson. Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* A4GALT 18149 NM_017436.6 3 GB3 synthase deficiency OMIM NOR polyagglutination syndrome OMIM AARS 20 NM_001605.2 2-21 Charcot-Marie-Tooth disease, axonal, type 2N OMIM Epileptic encephalopathy, early infantile, 29 OMIM AARS2 21022 NM_020745.3 1-22 Mitochondrial alanyl-tRNA synthetase deficiency OMIM Combined oxidative phosphorylation deficiency type 8; progressive leukoencephalopathy with ovarian failure OMIM file:///data/Metabolsk_v02-web.html 1/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* AASS 17366 NM_005763.3 2-24 ?-aminoadipic semialdehyde synthase deficiency OMIM Familial hyperlysinemia; saccharopinuria OMIM ABAT 23 NM_020686.5 2-16 GABA transaminase deficiency OMIM ABCA1 29 NM_005502.3 2-50 Tangier disease OMIM Analaphalipoproteinemia OMIM ABCB11 42 NM_003742.4 2-28 Bile salt export pump deficiency OMIM Progressive familial intrahepatic cholestasis type 2 (severe); benign recurrent intrahepatic cholestasis type 2 (milder) OMIM ABCB4 45 NM_000443.3 2-28 Phosphatidylcholine translocator deficiency OMIM Progressive familial intrahepatic cholestasis type 3 (severe); low phospholipid-associated cholelithiasis (milder) OMIM ABCB6 47 NM_005689.3 1-19 Mitochondrial porphyrin transporter deficiency OMIM Familial pseudohyperkalemia type 2; dyschromatosis universalis hereditaria type 3 OMIM ABCB7 48 NM_004299.6 1-16 ABCB7 deficiency OMIM Sideroblastic anemia and spinocerebellar ataxia OMIM ABCC2 53 NM_000392.5 1-32 Canalicular bilirubin glucuronide transporter deficiency OMIM Dubin-Johnson syndrome OMIM ABCC6 57 NM_001171.5 1-9 1-31 ABCC6 deficiency OMIM Generalized arterial calcification of infancy type 2 (severe); pseudoxanthoma elasticum (milder) OMIM file:///data/Metabolsk_v02-web.html 2/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* ABCC8 59 NM_000352.4 1-39 ATP-sensitive potassium channel regulatory subunit deficiency OMIM Familial hyperinsulinemic hypoglycemia type 1 OMIM ATP-sensitive potassium channel regulatory subunit superactivity OMIM Developmental delay, epilepsy and neonatal diabetes (DEND), permanent or transient neonatal diabetes without neurologic features (severe); maturity- onset diabetes of the young type 12 (milder) OMIM ABCD1 61 NM_000033.3 7-10 1-10 X-linked adrenoleukodystrophy OMIM ABCD3 67 NM_002858.3 1-23 PMP70 deficiency OMIM ABCD4 68 NM_005050.3 1-19 Methylmalonic aciduria and homocystinuria,+cblJ+type OMIM ABCG5 13886 NM_022436.2 1-13 Sitosterolemia due to ABCG5 deficiency OMIM ABCG8 13887 NM_022437.2 1-13 Sitosterolemia due to ABCG8 deficiency OMIM ABHD12 15868 NM_001042472.2 1-13 ABHD12 deficiency OMIM Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) syndrome, OMIM ABHD5 21396 NM_016006.5 1-7 CGI-58 deficiency OMIM Chanarin-Dorfman syndrome; neutral lipid storage disease with ichthyosis OMIM ACACA 84 NM_198839.2 7-60 Cytosolic acetyl-CoA carboxylase 1 deficiency OMIM ACACB 85 NM_001093.3 1-52 Mitochondrial acetyl-CoA carboxylase 2 deficiency OMIM ACAD8 87 NM_014384.2 1-11 Isobutyryl- CoA+dehydrogenase+deficiency OMIM file:///data/Metabolsk_v02-web.html 3/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* ACAD9 21497 NM_014049.4 1-18 ACAD9 deficiency OMIM ACADL 88 NM_001608.3 1-11 Long-chain acyl-CoA dehydrogenase deficiency OMIM ACADM 89 NM_000016.5 1-12 Medium-chain acyl-CoA dehydrogenase deficiency OMIM ACADS 90 NM_000017.3 1-10 Short-chain acyl-CoA dehydrogenase deficiency OMIM ACADSB 91 NM_001609.3 1-11 2-Methylbutyryl- CoA+dehydrogenase+deficiency OMIM Short/branched-chain acyl- CoA+dehydrogenase deficiency; 2- methylbutyrylglycinuria OMIM ACADVL 92 NM_000018.3 1-20 Very long-chain acyl-CoA dehydrogenase deficiency OMIM ACAT1 93 NM_000019.3 1-12 Mitochondrial acetoacetyl-CoA thiolase deficiency OMIM ?-ketothiolase deficiency; ?- methylacetoacetic aciduria OMIM ACAT2 11178 NM_005891.2 1-9 Cytosolic acetoacetyl-CoA thiolase deficiency OMIM ACBD5 23338 NM_145698.4 1-13 Acyl-CoA-binding domain-containing protein 5 deficiency OMIM ACER3 16066 NM_018367.6 1-11 Alkaline ceramidase 3 deficiency OMIM ACMSD 19288 NM_138326.2 1-10 Aminocarboxymuconate semialdehyde decarboxylase superactivity OMIM ACO2 118 NM_001098.2 1-18 Mitochondrial aconitase deficiency OMIM Infantile cerebellar-retinal degeneration OMIM ACOX1 119 NM_004035.6 1-14 Peroxisomal straight-chain acyl-CoA oxidase deficiency OMIM Pseudo-neonatal adrenoleukodystrophy OMIM file:///data/Metabolsk_v02-web.html 4/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* ACOX2 120 NM_003500.3 2-15 Peroxisomal branched-chain acyl-CoA oxidase deficiency OMIM Congenital bile acid synthesis defect type 6 OMIM ACSF3 27288 NM_174917.4 3-11 Acyl-CoA+synthetase family member 3 deficiency OMIM Combined malonic and methylmalonic aciduria OMIM ACSL4 3571 NM_004458.2 3-16 Long-chain fatty acid-CoA ligase 4 deficiency OMIM X-linked mental retardation 63 OMIM ACY1 177 NM_000666.2 2-15 Aminoacylase 1 deficiency OMIM ADA 186 NM_000022.3 1-12 Adenosine deaminase 1 deficiency OMIM ADAR 225 NM_001111.5 1-15 RNA-specific adenosine deaminase deficiency OMIM Aicardi-GoutiEres syndrome type 6 (recessive); dyschromatosis symmetrica hereditaria (dominant) OMIM ADCK3 16812 NM_020247.4 2-15 COQ8A deficiency OMIM Primary coenzyme Q10 deficiency type 4; ADCK3 deficiency OMIM ADCK4 19041 NM_024876.3 2-15 COQ8B deficiency OMIM Nephrotic syndrome type 9; ADCK4 deficiency OMIM ADK 257 NM_001123.3 1-11 =+adenosine kinase deficiency OMIM ADSL 291 NM_000026.3 1-13 Adenylosuccinate lyase deficiency OMIM AFG3L2 315 NM_006796.2 14 1-17 m-AAA protease AFG3L2 subunit deficiency OMIM Autosomal recessive spastic ataxia type 5; spinocerebellar ataxia type 28 OMIM AGA 318 NM_000027.3 1-9 Aspartylglucosaminidase deficiency OMIM Aspartylglucosaminuria OMIM file:///data/Metabolsk_v02-web.html 5/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* AGK 21869 NM_018238.3 16 2-16 Acylglycerol kinase deficiency OMIM Sengers syndrome OMIM AGL 321 NM_000642.2 2-34 Glycogen debranching enzyme deficiency OMIM Glycogen storage disease type 3; Cori- Forbes disease; limit dextrinosis OMIM AGPAT2 325 NM_006412.3 1-6 Lysophosphatidic acid acyltransferase+deficiency OMIM Congenital generalized lipodystrophy type 1, Berardinelli-Seip syndrome OMIM AGPS 327 NM_003659.3 1-20 Alkylglycerone 3-phosphate synthase deficiency OMIM Rhizomelic chondrodysplasia punctata type 3 OMIM AGXT 341 NM_000030.2 1-11 Alanine-glyoxylate aminotransferase deficiency OMIM Primary hyperoxaluria type 1 OMIM AGXT2 14412 NM_031900.3 1-14 Hyper-?-aminoisobutyric aciduria OMIM AHCY 343 NM_000687.3 1-10 S-adenosylhomocysteine hydrolase deficiency OMIM AICDA 13203 NM_020661.3 1-5 Activation-induced cytidine deaminase deficiency OMIM Hyper-IgM syndrome type 2 OMIM AIFM1 8768 NM_004208.3 1-16 AIFM1 deficiency OMIM Combined oxidative phosphorylation deficiency type 6; Cowchock syndrome OMIM AK1 361 NM_000476.2 2-7 Adenylate kinase 1 deficiency OMIM AK2 362 NM_001625.3 1-6 Adenylate kinase 2 deficiency OMIM Reticular dysgenesis OMIM AK7 20091 NM_152327.4 1-18 Adenylate kinase 7 deficiency OMIM file:///data/Metabolsk_v02-web.html 6/101 2/1/2021 Metabolske sykdommer v02 Ekson Gen Gen (HGNC affisert (HGNC Transkript Ekson** Fenotype symbol) av ID) segdup* AKR1D1 388 NM_005989.3 1-9 ?4-3-oxosteroid 5?-reductase deficiency OMIM Congenital bile acid synthesis defect type 2 OMIM AKT2 392 NM_001626.5 2-14 AKT2 superactivity OMIM Hypoinsulinemic hypoglycemia with hemihypertrophy OMIM AKT2 deficiency OMIM ALAD 395 NM_000031.5 2-12 ?-aminolevulinic acid dehydratase deficiency OMIM ALAS2 397 NM_000032.5 2-11 ?-aminolevulinic acid synthase deficiency OMIM X-linked recessive sideroblastic anemia type 1 OMIM ?-aminolevulinic acid synthase superactivity OMIM X-linked protoporphyria OMIM ALDH18A1 9722 NM_002860.3 2-18 ?-1-pyrroline-5-carboxylate synthase deficiency, cutis laxa phenotype OMIM Autosomal recessive cutis laxa type 3A; autosomal dominant cutis laxa type 3 OMIM ?-1-pyrroline-5-carboxylate synthase deficiency, spastic paraplegia phenotype OMIM Autosomal dominant spastic paraplegia type 9A; autosomal recessive spastic paraplegia type 9B OMIM ALDH1A3 409 NM_000693.3 1-13 Retinaldehyde dehydrogenase 3 deficiency OMIM Isolated microphthalmia type 8 OMIM ALDH3A2
Load more

Recommended publications
  • The Diversity of Dolichol-Linked Precursors to Asn-Linked Glycans Likely Results from Secondary Loss of Sets of Glycosyltransferases
    The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases John Samuelson*†, Sulagna Banerjee*, Paula Magnelli*, Jike Cui*, Daniel J. Kelleher‡, Reid Gilmore‡, and Phillips W. Robbins* *Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 715 Albany Street, Boston, MA 02118-2932; and ‡Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, MA 01665-0103 Contributed by Phillips W. Robbins, December 17, 2004 The vast majority of eukaryotes (fungi, plants, animals, slime mold, to N-glycans of improperly folded proteins, which are retained in and euglena) synthesize Asn-linked glycans (Alg) by means of a the ER by conserved glucose-binding lectins (calnexin͞calreticulin) lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3. Knowledge of (13). Although the Alg glycosyltransferases in the lumen of ER this pathway is important because defects in the glycosyltrans- appear to be eukaryote-specific, archaea and Campylobacter sp. ferases (Alg1–Alg12 and others not yet identified), which make glycosylate the sequon Asn and͞or contain glycosyltransferases dolichol-PP-glycans, lead to numerous congenital disorders of with domains like those of Alg1, Alg2, Alg7, and STT3 (1, 14–16). glycosylation. Here we used bioinformatic and experimental Protists, unicellular eukaryotes, suggest three notable exceptions methods to characterize Alg glycosyltransferases and dolichol- to the N-linked glycosylation path described in yeast and animals PP-glycans of diverse protists, including many human patho- (17). First, the kinetoplastid Trypanosoma cruzi (cause of Chagas gens, with the following major conclusions. First, it is demon- myocarditis), fails to glucosylate the dolichol-PP-linked precursor strated that common ancestry is a useful method of predicting and so makes dolichol-PP-GlcNAc2Man9 (18).
    [Show full text]
  • Supplemental Figure 1. Vimentin
    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
    [Show full text]
  • Implications in Parkinson's Disease
    Journal of Clinical Medicine Review Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease Silvia Paciotti 1,2 , Elisabetta Albi 3 , Lucilla Parnetti 1 and Tommaso Beccari 3,* 1 Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy; [email protected] (S.P.); [email protected] (L.P.) 2 Section of Physiology and Biochemistry, Department of Experimental Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy 3 Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti, 06123 Perugia, Italy; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 20 February 2020; Published: 21 February 2020 Abstract: Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease. Keywords: ceramide metabolism; Parkinson’s disease; α-synuclein; GBA; GLA; HEX A-B; GALC; ASAH1; SMPD1; ARSA * Correspondence [email protected] 1.
    [Show full text]
  • Structural Characterization of Polysaccharides from Cordyceps Militaris and Their Hypolipidemic Effects Cite This: RSC Adv.,2018,8,41012 in High Fat Diet Fed Mice†
    RSC Advances View Article Online PAPER View Journal | View Issue Structural characterization of polysaccharides from Cordyceps militaris and their hypolipidemic effects Cite this: RSC Adv.,2018,8,41012 in high fat diet fed mice† Zhen-feng Huang, ‡ Ming-long Zhang,‡ Song Zhang,* Ya-hui Wang and Xue-wen Jiang Cordyceps militaris is a crude dietary therapeutic mushroom with high nutritional and medicinal values. Mushroom-derived polysaccharides have been found to possess antihyperglycemic and antihyperlipidemic activities. This study aimed to partially clarify the structural characterization and comparatively evaluate hypolipidemic potentials of intracellular- (IPCM) and extracellular polysaccharides of C. militaris (EPCM) in high fat diet fed mice. Results indicated that IPCM-2 is a-pyran polysaccharide with an average molecular weight of 32.5 kDa, was mainly composed of mannose, glucose and galactose with mass percentages of 51.94%, 10.54%, and 37.25%, respectively. EPCM-2 is an a-pyran Creative Commons Attribution 3.0 Unported Licence. polysaccharide with an average molecular weight of 20 kDa that is mainly composed of mannose, glucose and galactose with mass percentages of 44.51%, 18.33%, and 35.38%, respectively. In in vivo study, EPCM-1 treatment (100 mg kgÀ1 dÀ1) showed potential effects on improving serum lipid profiles of hyperlipidemic mice, reflected by decreasing serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) levels by 20.05%, 45.45% and 52.63%, respectively, while IPCM-1 treatment
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Broad and Thematic Remodeling of the Surface Glycoproteome on Isogenic
    bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Broad and thematic remodeling of the surface glycoproteome on isogenic cells transformed with driving proliferative oncogenes Kevin K. Leung1,5, Gary M. Wilson2,5, Lisa L. Kirkemo1, Nicholas M. Riley2,4, Joshua J. Coon2,3, James A. Wells1* 1Department of Pharmaceutical Chemistry, UCSF, San Francisco, CA, USA Departments of Chemistry2 and Biomolecular Chemistry3, University of Wisconsin- Madison, Madison, WI, 53706, USA 4Present address Department of Chemistry, Stanford University, Stanford, CA, 94305, USA 5These authors contributed equally *To whom correspondence should be addressed bioRxiv preprint doi: https://doi.org/10.1101/808139; this version posted October 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract: The cell surface proteome, the surfaceome, is the interface for engaging the extracellular space in normal and cancer cells. Here We apply quantitative proteomics of N-linked glycoproteins to reveal how a collection of some 700 surface proteins is dramatically remodeled in an isogenic breast epithelial cell line stably expressing any of six of the most prominent proliferative oncogenes, including the receptor tyrosine kinases, EGFR and HER2, and downstream signaling partners such as KRAS, BRAF, MEK and AKT.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]